CD8A and neoplasm: FC and immunochemistry (IHC) revealed that while losartan in combination with anti-PD-1 did not exert a significant effect on anti-PD-1-induced CD8+ T cell reinvigoration or CD8+ T cell activation markers, it increased tumor infiltration by CD8+CD3+ T cells, CD3+CD8− helper T cells (CD4+), CD3−CD8+ plasmacytoid dendritic (pDC) cells, and CD45+ immune cells compared to anti-PD-1 alone (Fig. 2 D–G and SI Appendix, Fig. S2 I–K).